>Intermune’s spike Monday of $5.05, to $18.43 added roughly $200 million to ITMN’s market cap. This an example of what mildly positive news on a HCV drug trial can do to a stock.<
VRUS’ spike based on early HCV data has been even more spectacular.
>Cash in the bank, a strong partner and an approved drug in Tyzeka limit the downside. Given the pipeline includes another HCV drug (IDX 102) and a HIV drug in IDX899, I like the risk-reward proposition that Idenix offers.<
No question.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
